Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Janux Therapeutics Inc (JANX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/11/2025: JANX (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 40.71% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 03/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.58B USD | Price to earnings Ratio - | 1Y Target Price 86.69 |
Price to earnings Ratio - | 1Y Target Price 86.69 | ||
Volume (30-day avg) 914363 | Beta 3.22 | 52 Weeks Range 26.07 - 71.71 | Updated Date 04/2/2025 |
52 Weeks Range 26.07 - 71.71 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.28 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -933.58% |
Management Effectiveness
Return on Assets (TTM) -8.57% | Return on Equity (TTM) -10.09% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 582460991 | Price to Sales(TTM) 149.66 |
Enterprise Value 582460991 | Price to Sales(TTM) 149.66 | ||
Enterprise Value to Revenue 55.01 | Enterprise Value to EBITDA -33.8 | Shares Outstanding 59105100 | Shares Floating 37290619 |
Shares Outstanding 59105100 | Shares Floating 37290619 | ||
Percent Insiders 7.05 | Percent Institutions 113.46 |
Analyst Ratings
Rating 4.79 | Target Price 90.23 | Buy 1 | Strong Buy 12 |
Buy 1 | Strong Buy 12 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Janux Therapeutics Inc
Company Overview
History and Background
Janux Therapeutics Inc. is a biopharmaceutical company focused on developing innovative immunotherapies for cancer. Founded in 2017, it has advanced its TRACTr (T cell Activating Redirected Cytokine) platform technology. The company went public in 2021.
Core Business Areas
- TRACTr Platform: Development of TRACTr-based immunotherapies, which aim to redirect and activate T cells to kill tumor cells while minimizing systemic toxicity.
Leadership and Structure
The leadership team includes David Segal (CEO), and the organizational structure includes research, development, and clinical operations departments.
Top Products and Market Share
Key Offerings
- JANX007: JANX007 is Janux's lead program, targeting PSMA for prostate cancer. It is currently in Phase 1 clinical trials. Market share data is unavailable as it is still in clinical development. Competitors in prostate cancer therapies include companies developing antibody-drug conjugates (ADCs) and other immunotherapies.
- JANX008: JANX008 targets EGFR for solid tumors and is in preclinical development. Market share is unavailable as it's in preclinical stage. Competitors in EGFR-targeted therapies include companies with EGFR inhibitors and antibodies.
Market Dynamics
Industry Overview
The immunotherapy market is experiencing significant growth, driven by advances in immuno-oncology and increasing demand for targeted therapies. Key trends include the development of novel bispecific antibodies, cell therapies, and immune checkpoint inhibitors.
Positioning
Janux Therapeutics is positioned as an innovator in the immunotherapy space, leveraging its TRACTr platform to develop differentiated cancer therapies. Its competitive advantage lies in the potential for improved efficacy and reduced toxicity compared to traditional immunotherapies.
Total Addressable Market (TAM)
The total addressable market for cancer immunotherapies is projected to reach hundreds of billions of dollars. Janux is positioned to capture a portion of this market by developing therapies for specific cancer types with high unmet needs.
Upturn SWOT Analysis
Strengths
- Novel TRACTr platform technology
- Strong preclinical data
- Experienced management team
- Targeting of validated cancer targets
Weaknesses
- Early-stage clinical development
- Dependence on a single technology platform
- Limited financial resources compared to larger pharmaceutical companies
- High attrition rate in drug development
Opportunities
- Expansion of TRACTr platform to other cancer targets
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results for lead programs
- Potential for orphan drug designation
Threats
- Competition from established immunotherapy players
- Regulatory hurdles
- Clinical trial failures
- Patent challenges
Competitors and Market Share
Key Competitors
- MRTX
- XNCR
- INAB
Competitive Landscape
Janux's TRACTr platform offers a novel approach to immunotherapy. Its success will depend on demonstrating superior efficacy and safety compared to existing therapies from established players.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Since the company went public in 2021, historical growth can be based on stock appreciation and the progress of its clinical trials.
Future Projections: Future growth depends on the clinical success of its lead programs and the expansion of its pipeline. Analyst estimates can vary based on trial results.
Recent Initiatives: Recent initiatives include the advancement of JANX007 into Phase 1 clinical trials and the continued development of its TRACTr platform.
Summary
Janux Therapeutics is an early-stage biopharmaceutical company with a novel TRACTr platform technology for developing cancer immunotherapies. The company's success hinges on the positive outcomes of its clinical trials. It faces competition from larger, more established companies and the inherent risks of drug development. Securing partnerships and expanding its pipeline are crucial for long-term growth.
Similar Companies
- MRTX
- XNCR
- INAB
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Janux Therapeutics Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2021-06-11 | President, CEO & Director Dr. David Alan Campbell Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 81 | Website https://www.januxrx.com |
Full time employees 81 | Website https://www.januxrx.com | ||
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients with cancer. Its clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.